5:31 PM
 | 
Dec 12, 2011
 |  BC Extra  |  Company News

FDA approves crush-resistant Opana

Endo Pharmaceuticals Holdings Inc. (NASDAQ:ENDP) said FDA approved a crush-resistant formulation of Opana ER oxymorphone...

Read the full 63 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >